Teva Pharmaceutical Industries (TEVA) Common Equity (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Common Equity came in at $7.8 billion in Q2 2026, up 13.51% YoY from $6.8 billion in Q2 2025, and down 5.77% on a QoQ basis from $8.2 billion in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Common Equity (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Common Equity data on file, last reported at $7.8 billion in Q2 2026.
- Quarterly Common Equity rose 13.51% year-over-year to $7.8 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $7.8 billion (up 13.51% YoY) and the FY2025 annual result came in at $7.9 billion, up 47.1% from the prior year.
- Common Equity slipped to $7.8 billion in Q2 2026, from $8.2 billion in the prior quarter.
- In the past five years, Common Equity ranged from a high of $10.3 billion in Q1 2022 to a low of $5.4 billion in Q4 2024.
- A 5-year average of $7.8 billion and a median of $7.7 billion in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity plunged 33.79% — and 2025, when it surged 47.1%.
- Tracing TEVA's Common Equity over 5 years: stood at $8.6 billion in 2022, then decreased by 5.49% to $8.1 billion in 2023, then sank by 33.79% to $5.4 billion in 2024, then soared by 47.1% to $7.9 billion in 2025, then decreased by 1.98% to $7.8 billion in 2026.
- The last three Common Equity figures came in at $7.8 billion (Q2 2026), $8.2 billion (Q1 2026), and $7.9 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 4.05 Bn |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | 1.81 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.76 Bn |
| Mar 31, 2026 | 8.23 Bn |
| Dec 31, 2025 | 7.91 Bn |
| Sep 30, 2025 | 7.25 Bn |
| Jun 30, 2025 | 6.83 Bn |
| Mar 31, 2025 | 6.27 Bn |
| Dec 31, 2024 | 5.38 Bn |
| Sep 30, 2024 | 6.38 Bn |
| Jun 30, 2024 | 6.56 Bn |
| Mar 31, 2024 | 7.54 Bn |
| Dec 31, 2023 | 8.13 Bn |
| Sep 30, 2023 | 7.39 Bn |
| Jun 30, 2023 | 7.59 Bn |
| Mar 31, 2023 | 8.50 Bn |
| Dec 31, 2022 | 8.60 Bn |
| Sep 30, 2022 | 9.51 Bn |
| Jun 30, 2022 | 9.81 Bn |
| Mar 31, 2022 | 10.26 Bn |
| Dec 31, 2021 | 11.24 Bn |
| Sep 30, 2021 | 11.45 Bn |